MedPath

TAIHO ONCOLOGY INC

TAIHO ONCOLOGY INC logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

39

Active:26
Completed:3

Trial Phases

3 Phases

Phase 1:32
Phase 2:2
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (38 trials with phase data)• Click on a phase to view related trials

Phase 1
32 (84.2%)
Phase 2
2 (5.3%)
Phase 3
2 (5.3%)
phase_1_2
1 (2.6%)
phase_2_3
1 (2.6%)
No trials found

News

UCLA Researchers Receive $950,000 Grant to Launch Multi-Institutional Trial of Zipalertinib for EGFR-Mutated Cancers

UCLA's Arjan Gower received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to launch a multi-institutional clinical trial testing zipalertinib.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.